Rare disease trials are particularly challenging because small patient populations and wide variation in symptoms make endpoint definition difficult. In this short video, Marc Buyse shows how IDDI combined biomarker and clinical outcomes to design an endpoint strategy for a Wilson’s disease trial that supported both US and European regulatory pathways.
Looking to accelerate decision-making in oncology prevention trials? Explore how early endpoint strategies can support earlier development decisions.
Want to improve probability of success in phase 3 oncology trials? See how adaptive Bayesian design can help identify responding patient populations.
Key Challenges in Rare Disease Trials
- Small patient populations limit statistical power
- Symptoms and disease progression vary significantly across patients
- Difficulty selecting endpoints applicable across diverse populations
- Regulatory expectations for robust and clinically meaningful results
The IDDI Approach
Drawing on deep expertise and biostatistical excellence, IDDI:
- Identified copper concentration as a key biomarker endpoint
- Designed a Net Treatment Benefit analysis using prioritized outcomes
- Combined biomarker and clinical endpoints to address heterogeneity
- Supported a strategy aligned with both FDA and European regulatory pathways
Sponsor Benefit
- Maximize the value of available clinical and biomarker data
- Reduce risk of inconclusive or non-approvable trials
- Support both accelerated and full approval strategies
- Improve decision-making in complex rare disease development programs
Planning a rare disease or complex clinical trial?
Talk to our statistical experts about designing endpoints that support regulatory success while reflecting real patient outcomes.
Read the full video transcript
Identifying the right trial endpoints is an important, but often challenging part of study design. IDDI worked with a company that was designing a trial for patients with Wilson’s disease, a rare inherited disease that causes excessive copper accumulation in the body and this affects several organs, especially the liver and the brain. The disease is actually caused by a genetic mutation that impairs the liver to process copper. The challenge in this situation is the rarity of the disease as well as its heterogeneity, as different patients have widely different symptoms, which makes it very challenging both to select a specific patient population, and also to come up with endpoints that can be measured across a wide range of symptoms of the disease. We knew that copper concentration is an important endpoint, but it is a biomarker than a directly relevant clinical endpoint, which helped us get accelerated approval for the drug in the US. We also suggested a Net Treatment Benefit analysis using multiple prioritized outcomes in order to get the drug approved in Europe as well. This work was undertaken with our sister company, One2Treat.
